Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis

Masaaki Mori, Masue Imaizumi, Naruhiko Ishiwada, Takashi Kaneko, Hiroaki Goto, Koji Kato, Junichi Hara, Yoshiyuki Kosaka, Kazutoshi Koike, Hiroshi Kawamoto, Naoko Maeda, Tomoko Yoshinari, Hiroyuki Kishino, Kenichi Takahashi, Shizuko Kawahara, Nicholas A. Kartsonis, Yoshihiro Komada

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

The antifungal agents approved in Japan for pediatric use are limited and many unapproved drugs are actually used without clear instruction for dosage. We investigated the pharmacokinetics of caspofungin for the treatment of invasive candidiasis and invasive aspergillosis in 20 Japanese pediatric patients using a pediatric-specific dosage based on body surface area. Caspofungin was administered intravenously over 60min as 70mg/m2 on Day 1, followed by 50mg/m2 per day. Five or 4 point blood sampling were done in 15 patients on Day 4-5 to calculate AUC0-24h. The geometric means (95% confidence interval) of C24h and AUC0-24h in the pediatric patients were 3.3(2.5, 4.4)μg/mL and 175.1 (139.3, 220.1)μghr/mL, respectively, which were comparable to those in Japanese adult patients [3.2 (2.8, 3.5)μg/mL and 144.9 (131.7, 159.3)μghr/mL, respectively]. Among the 20 patients, 10 (50%) had at least 1 drug-related adverse event which was considered related to caspofungin therapy. No drug-related serious adverse event and no death occurred. The most common drug-related adverse events were events relating to hepatic function (mainly increases in ALT and AST). The overall success in efficacy was observed in 13 of 20 patients. In conclusion, once daily administration of caspofungin (70mg/m2 on Day 1, followed by 50mg/m2 [maximum daily dose not to exceed 70mg]), which is the same dosage being used in overseas, achieved sufficient drug exposure and a favorable efficacy and acceptable safety profile in Japanese pediatric patients with invasive fungal infections.

Original languageEnglish
Pages (from-to)421-426
Number of pages6
JournalJournal of Infection and Chemotherapy
Volume21
Issue number6
DOIs
Publication statusPublished - Jun 1 2015
Externally publishedYes

Fingerprint

caspofungin
Invasive Candidiasis
Aspergillosis
Pharmacokinetics
Pediatrics
Safety
Drug-Related Side Effects and Adverse Reactions
Pharmaceutical Preparations
Antifungal Agents
Body Surface Area
Japan

All Science Journal Classification (ASJC) codes

  • Microbiology (medical)
  • Pharmacology (medical)
  • Infectious Diseases

Cite this

Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis. / Mori, Masaaki; Imaizumi, Masue; Ishiwada, Naruhiko; Kaneko, Takashi; Goto, Hiroaki; Kato, Koji; Hara, Junichi; Kosaka, Yoshiyuki; Koike, Kazutoshi; Kawamoto, Hiroshi; Maeda, Naoko; Yoshinari, Tomoko; Kishino, Hiroyuki; Takahashi, Kenichi; Kawahara, Shizuko; Kartsonis, Nicholas A.; Komada, Yoshihiro.

In: Journal of Infection and Chemotherapy, Vol. 21, No. 6, 01.06.2015, p. 421-426.

Research output: Contribution to journalArticle

Mori, M, Imaizumi, M, Ishiwada, N, Kaneko, T, Goto, H, Kato, K, Hara, J, Kosaka, Y, Koike, K, Kawamoto, H, Maeda, N, Yoshinari, T, Kishino, H, Takahashi, K, Kawahara, S, Kartsonis, NA & Komada, Y 2015, 'Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis', Journal of Infection and Chemotherapy, vol. 21, no. 6, pp. 421-426. https://doi.org/10.1016/j.jiac.2015.01.009
Mori, Masaaki ; Imaizumi, Masue ; Ishiwada, Naruhiko ; Kaneko, Takashi ; Goto, Hiroaki ; Kato, Koji ; Hara, Junichi ; Kosaka, Yoshiyuki ; Koike, Kazutoshi ; Kawamoto, Hiroshi ; Maeda, Naoko ; Yoshinari, Tomoko ; Kishino, Hiroyuki ; Takahashi, Kenichi ; Kawahara, Shizuko ; Kartsonis, Nicholas A. ; Komada, Yoshihiro. / Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis. In: Journal of Infection and Chemotherapy. 2015 ; Vol. 21, No. 6. pp. 421-426.
@article{e54e70fd570d4901a4335d7b6a823b34,
title = "Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis",
abstract = "The antifungal agents approved in Japan for pediatric use are limited and many unapproved drugs are actually used without clear instruction for dosage. We investigated the pharmacokinetics of caspofungin for the treatment of invasive candidiasis and invasive aspergillosis in 20 Japanese pediatric patients using a pediatric-specific dosage based on body surface area. Caspofungin was administered intravenously over 60min as 70mg/m2 on Day 1, followed by 50mg/m2 per day. Five or 4 point blood sampling were done in 15 patients on Day 4-5 to calculate AUC0-24h. The geometric means (95{\%} confidence interval) of C24h and AUC0-24h in the pediatric patients were 3.3(2.5, 4.4)μg/mL and 175.1 (139.3, 220.1)μghr/mL, respectively, which were comparable to those in Japanese adult patients [3.2 (2.8, 3.5)μg/mL and 144.9 (131.7, 159.3)μghr/mL, respectively]. Among the 20 patients, 10 (50{\%}) had at least 1 drug-related adverse event which was considered related to caspofungin therapy. No drug-related serious adverse event and no death occurred. The most common drug-related adverse events were events relating to hepatic function (mainly increases in ALT and AST). The overall success in efficacy was observed in 13 of 20 patients. In conclusion, once daily administration of caspofungin (70mg/m2 on Day 1, followed by 50mg/m2 [maximum daily dose not to exceed 70mg]), which is the same dosage being used in overseas, achieved sufficient drug exposure and a favorable efficacy and acceptable safety profile in Japanese pediatric patients with invasive fungal infections.",
author = "Masaaki Mori and Masue Imaizumi and Naruhiko Ishiwada and Takashi Kaneko and Hiroaki Goto and Koji Kato and Junichi Hara and Yoshiyuki Kosaka and Kazutoshi Koike and Hiroshi Kawamoto and Naoko Maeda and Tomoko Yoshinari and Hiroyuki Kishino and Kenichi Takahashi and Shizuko Kawahara and Kartsonis, {Nicholas A.} and Yoshihiro Komada",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.jiac.2015.01.009",
language = "English",
volume = "21",
pages = "421--426",
journal = "Journal of Infection and Chemotherapy",
issn = "1341-321X",
publisher = "Elsevier BV",
number = "6",

}

TY - JOUR

T1 - Pharmacokinetics, efficacy, and safety of caspofungin in Japanese pediatric patients with invasive candidiasis and invasive aspergillosis

AU - Mori, Masaaki

AU - Imaizumi, Masue

AU - Ishiwada, Naruhiko

AU - Kaneko, Takashi

AU - Goto, Hiroaki

AU - Kato, Koji

AU - Hara, Junichi

AU - Kosaka, Yoshiyuki

AU - Koike, Kazutoshi

AU - Kawamoto, Hiroshi

AU - Maeda, Naoko

AU - Yoshinari, Tomoko

AU - Kishino, Hiroyuki

AU - Takahashi, Kenichi

AU - Kawahara, Shizuko

AU - Kartsonis, Nicholas A.

AU - Komada, Yoshihiro

PY - 2015/6/1

Y1 - 2015/6/1

N2 - The antifungal agents approved in Japan for pediatric use are limited and many unapproved drugs are actually used without clear instruction for dosage. We investigated the pharmacokinetics of caspofungin for the treatment of invasive candidiasis and invasive aspergillosis in 20 Japanese pediatric patients using a pediatric-specific dosage based on body surface area. Caspofungin was administered intravenously over 60min as 70mg/m2 on Day 1, followed by 50mg/m2 per day. Five or 4 point blood sampling were done in 15 patients on Day 4-5 to calculate AUC0-24h. The geometric means (95% confidence interval) of C24h and AUC0-24h in the pediatric patients were 3.3(2.5, 4.4)μg/mL and 175.1 (139.3, 220.1)μghr/mL, respectively, which were comparable to those in Japanese adult patients [3.2 (2.8, 3.5)μg/mL and 144.9 (131.7, 159.3)μghr/mL, respectively]. Among the 20 patients, 10 (50%) had at least 1 drug-related adverse event which was considered related to caspofungin therapy. No drug-related serious adverse event and no death occurred. The most common drug-related adverse events were events relating to hepatic function (mainly increases in ALT and AST). The overall success in efficacy was observed in 13 of 20 patients. In conclusion, once daily administration of caspofungin (70mg/m2 on Day 1, followed by 50mg/m2 [maximum daily dose not to exceed 70mg]), which is the same dosage being used in overseas, achieved sufficient drug exposure and a favorable efficacy and acceptable safety profile in Japanese pediatric patients with invasive fungal infections.

AB - The antifungal agents approved in Japan for pediatric use are limited and many unapproved drugs are actually used without clear instruction for dosage. We investigated the pharmacokinetics of caspofungin for the treatment of invasive candidiasis and invasive aspergillosis in 20 Japanese pediatric patients using a pediatric-specific dosage based on body surface area. Caspofungin was administered intravenously over 60min as 70mg/m2 on Day 1, followed by 50mg/m2 per day. Five or 4 point blood sampling were done in 15 patients on Day 4-5 to calculate AUC0-24h. The geometric means (95% confidence interval) of C24h and AUC0-24h in the pediatric patients were 3.3(2.5, 4.4)μg/mL and 175.1 (139.3, 220.1)μghr/mL, respectively, which were comparable to those in Japanese adult patients [3.2 (2.8, 3.5)μg/mL and 144.9 (131.7, 159.3)μghr/mL, respectively]. Among the 20 patients, 10 (50%) had at least 1 drug-related adverse event which was considered related to caspofungin therapy. No drug-related serious adverse event and no death occurred. The most common drug-related adverse events were events relating to hepatic function (mainly increases in ALT and AST). The overall success in efficacy was observed in 13 of 20 patients. In conclusion, once daily administration of caspofungin (70mg/m2 on Day 1, followed by 50mg/m2 [maximum daily dose not to exceed 70mg]), which is the same dosage being used in overseas, achieved sufficient drug exposure and a favorable efficacy and acceptable safety profile in Japanese pediatric patients with invasive fungal infections.

UR - http://www.scopus.com/inward/record.url?scp=84939994473&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84939994473&partnerID=8YFLogxK

U2 - 10.1016/j.jiac.2015.01.009

DO - 10.1016/j.jiac.2015.01.009

M3 - Article

VL - 21

SP - 421

EP - 426

JO - Journal of Infection and Chemotherapy

JF - Journal of Infection and Chemotherapy

SN - 1341-321X

IS - 6

ER -